Related Experiment Video
Updated: Feb 22, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
LINE-1 as a therapeutic target for castration-resistant prostate cancer
Nadine Houede1, Pier Vincenzo Piazza2, Philippe Pourquier3
1Medical Oncology Department, Nimes University Hospital, Nimes, France, INSERM U1194, Montpellier Cancer Research Institute, and Montpellier University, France.
Abstract:
Prostate cancer is the third leading cause of death by cancer in men. Surgery or hormone deprivation usually contains the progression of the local forms of the disease. In metastatic situations, chemotherapy or second generation hormone therapies are used with an overall survival that never exceeds 36 months when tumors become resistant to castration. In the search for new alternatives, clinical trials with various classes of anticancer drugs have been performed, including chemotherapies, targeted therapies with kinase inhibitors, radium-223, or immunotherapies with somehow limited efficacy. Targeting LINE-1 with reverse transcriptase inhibitors was also proposed as an attractive strategy as retrotransposons may play a role in the initiation and the progression of prostate cancers. After reviewing the biological rational to use RT inhibitors in the treatment of prostate cancers, we will discuss the results of the phase II trial evaluating the efficacy of Efavirenz in the treatment of castration-resistant prostate cancers with a particular emphasis on pharmacokinetics data that were obtained. We will also discuss the positioning of other RT inhibitors in the current therapeutic armamentarium.
Insights
This study explores reverse transcriptase (RT) inhibitors, like Efavirenz, as a novel treatment for advanced prostate cancer. Findings suggest RT inhibitors may offer a new therapeutic avenue for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Current treatments for metastatic castration-resistant prostate cancer (mCRPC) have limited efficacy.
- Retrotransposons, like LINE-1, may contribute to prostate cancer progression.
Purpose of the Study:
- To review the rationale for using reverse transcriptase (RT) inhibitors in prostate cancer treatment.
- To present results from a phase II trial of Efavirenz in mCRPC patients.
- To discuss the potential role of RT inhibitors in the therapeutic landscape of prostate cancer.
Main Methods:
- Literature review on RT inhibitors and prostate cancer.
- Phase II clinical trial evaluating Efavirenz efficacy and pharmacokinetics in mCRPC.
- Analysis of existing therapeutic options for advanced prostate cancer.
Main Results:
- Efavirenz, an RT inhibitor, was evaluated in a phase II trial for mCRPC.
- Pharmacokinetic data from the Efavirenz trial were analyzed.
- The study discusses the potential of RT inhibitors, including Efavirenz, as a novel strategy.
Conclusions:
- RT inhibitors represent a promising strategy for prostate cancer, particularly mCRPC.
- Efavirenz's efficacy and pharmacokinetic profile warrant further investigation in mCRPC treatment.
- Targeting LINE-1 with RT inhibitors could offer a new therapeutic approach for prostate cancer.
